Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives.
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Antineoplastic Agents, Phytogenic
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ drug therapy
Celecoxib
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Humans
Luteolin
/ administration & dosage
Adjuvant therapy
Apoptosis
Breast cancer
Luteolin
Singling pathways/mechanisms
Journal
Phytomedicine : international journal of phytotherapy and phytopharmacology
ISSN: 1618-095X
Titre abrégé: Phytomedicine
Pays: Germany
ID NLM: 9438794
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
01
02
2019
revised:
06
03
2019
accepted:
09
03
2019
pubmed:
16
4
2019
medline:
17
9
2019
entrez:
16
4
2019
Statut:
ppublish
Résumé
Breast cancer is worldwide commonly found malignancy in women and effective treatment is regarded as a huge clinical challenge even in the presence of several options. Extensive literature is available that demonstrating polyphenols, the richly introduce phytopharmaceuticals as anticancer agents. Among these polyphenols, resveratrol, silibinin, quercetin, genistein, curcumin reported to have an awesome potential against breast cancer. However, till now no comprehensive survey found about the anticarcinogenic properties of luteolin against breast cancer. This review targeted the available literature on luteolin in the treatment of breast cancer, effects in combination with other anticancer drugs with possible mechanisms. An outstanding therapeutic potential of luteolin in the treatment of breast cancer has been recorded not just as a chemopreventive and chemotherapeutic agent yet complemented by its synergistic effects with other anticancer therapies such as cyclophosphamide, doxorubicin, and NSAID such as celecoxib, and possible underlying mechanisms. Ideally, this review will open new dimensions for luteolin as an effective and safe therapeutic agent in diminishing breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer is worldwide commonly found malignancy in women and effective treatment is regarded as a huge clinical challenge even in the presence of several options. Extensive literature is available that demonstrating polyphenols, the richly introduce phytopharmaceuticals as anticancer agents. Among these polyphenols, resveratrol, silibinin, quercetin, genistein, curcumin reported to have an awesome potential against breast cancer. However, till now no comprehensive survey found about the anticarcinogenic properties of luteolin against breast cancer.
SCOPE AND APPROACH
UNASSIGNED
This review targeted the available literature on luteolin in the treatment of breast cancer, effects in combination with other anticancer drugs with possible mechanisms.
KEY FINDINGS AND CONCLUSION
CONCLUSIONS
An outstanding therapeutic potential of luteolin in the treatment of breast cancer has been recorded not just as a chemopreventive and chemotherapeutic agent yet complemented by its synergistic effects with other anticancer therapies such as cyclophosphamide, doxorubicin, and NSAID such as celecoxib, and possible underlying mechanisms. Ideally, this review will open new dimensions for luteolin as an effective and safe therapeutic agent in diminishing breast cancer.
Identifiants
pubmed: 30986716
pii: S0944-7113(19)30053-4
doi: 10.1016/j.phymed.2019.152883
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antineoplastic Agents, Phytogenic
0
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Celecoxib
JCX84Q7J1L
Luteolin
KUX1ZNC9J2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
152883Informations de copyright
Copyright © 2019 Elsevier GmbH. All rights reserved.